Several biomarkers, including tumor mutation burden (TMB), PD‐L1 expression, microsatellite instability and tumor neoantigen‐related mutation burden (TNB), could effectively predict the overall response of treatments with anti‐PD‐1 antibodies in certain cancers.22 Here, CD274 is linked to neoplasm.